Catalyst Pharmaceuticals reports Q2 EPS (6c), consensus (8c)
"This quarter we were pleased to announce the FDA acceptance of our NDA for Firdapse(R) for Lambert-Eaton myasthenic syndrome and to receive Priority Review Status for our NDA," said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. "With the previous grant of Breakthrough Therapy Designation, the Priority Review underscores the robust potential of Firdapse and the need for a safe and effective FDA-approved treatment for LEMS. The recent appointment of our Chief Commercial Officer, Dan Brennan, provides us with extensive commercial experience that will help us build a commercial platform to prepare for a potential launch of Firdapse." At June 30, 2018, Catalyst had cash and investments of $73.4 million and no debt. Catalyst believes that its existing capital resources will be sufficient to support its planned operations through 2019.